Aprea Announces Positive Data from a Clinical Phase I/II Study with APR-246
News Sep 19, 2012
Aprea has announced positive data from a completed Phase I/II clinical study with its investigational drug APR-246. The results from the study have been published in the Journal of Clinical Oncology.
Based on the positive data, Aprea is planning to advance APR-246 into a Phase II proof-of-concept study in ovarian cancer. Aprea is a Karolinska Development portfolio company.
In the Phase I/II-trial, escalating doses of APR-246 were administered as monotherapy to 22 patients with advanced blood- or prostate cancer during up to four consecutive days.
Dose limiting toxicity was shown at plasma levels well above predicted therapeutic plasma levels.
The study also demonstrated dose-proportional and time-independent pharmacokinetics for APR-246 over the dose range studied.
The results from the study have been published in the Journal of Clinical Oncology.
In addition to reporting that the drug was well tolerated, the authors conclude from the study that APR-246 induces biological effects and that there are cases of clinical effects on tumor burden.
One patient with advanced blood cancer demonstrated a 50 percent reduction in the number of blast cells in the bone marrow.
Ulf Björklund, CEO, Aprea: “These are very encouraging study results. We are now planning to take the p53-activating compound APR-246 forward into a Phase II-trial in epithelial ovarian cancer with mutated p53 in combination with conventional chemotherapy.”
In the new proof-of-concept study, APR-246 will be administered in combination with the reintroduction of a carboplatin-based regimen.
A striking synergistic effect between APR-246 and the very active and frequently used cancer product carboplatin has been observed in pre-clinical experiments.
Torbjörn Bjerke, CEO, Karolinska Development: “This is indeed promising data. Although it was primarily a safety trial, the data indicates that APR-246 has an anti-tumor effect. APR-246 was well tolerated and, importantly, the safety profile is different from traditional cytostatic drugs. With these new results we can see a clear path forward for APR-246, especially in carboplatin-resistant patients.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018